Search

Your search keyword '"Du, Jin-Zhi"' showing total 222 results
Start Over Author "Du, Jin-Zhi"
222 results on '"Du, Jin-Zhi"'

10. Recent Progress on Nanomedicine‐Mediated Repolarization of Tumor‐Associated Macrophages for Cancer Immunotherapy.

Author

Zhang, Jing‐Yang, Su, Yun‐He, Wang, Xu, Yao, Xueqing, and Du, Jin‐Zhi

Abstract

Tumor‐associated macrophages (TAMs) constitute the largest number of immune cells in the tumor microenvironment (TME). They play an essential role in promoting tumor progression and metastasis, which makes them a potential therapeutic target for cancer treatment. TAMs are usually divided into two categories: pro‐tumoral M2‐like TAMs and antitumoral M1 phenotypes at either extreme. The reprogramming of M2‐like TAMs toward a tumoricidal M1 phenotype is of particular interest for the restoration of antitumor immunity in cancer immunotherapy. Notably, nanomedicines have shown great potential for cancer therapy due to their unique structures and properties. This review will briefly describe the biological features and roles of TAMs in tumor, and then discuss recent advances in nanomedicine‐mediated repolarization of TAMs for cancer immunotherapy. Finally, perspectives on nanomedicine‐mediated repolarization of TAMs for effective cancer immunotherapy are also presented. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Ferritin‐Based Nanocomposite Hydrogel Promotes Tumor Penetration and Enhances Cancer Chemoimmunotherapy.

Author

Liu, Rong, Liang, Qian, Luo, Jia‐Qi, Li, Yu‐Xuan, Zhang, Xin, Fan, Kelong, and Du, Jin‐Zhi

Subjects
HYDROGELS, IMMUNOGLOBULINS, BREAST tumors, LIGHTWEIGHT construction, DEXTRAN, NANOCOMPOSITE materials, FERRITIN, CANCER relapse
Abstract

Hydrogels are prevailing drug delivery depots to improve antitumor efficacy and reduce systemic toxicity. However, the application of conventional free drug‐loaded hydrogel is hindered by poor drug penetration in solid tumors. Here, an injectable ferritin‐based nanocomposite hydrogel is constructed to facilitate tumor penetration and improve cancer chemoimmunotherapy. Specifically, doxorubicin‐loaded human ferritin (Dox@HFn) and oxidized dextran (Dex‐CHO) are used to construct the injectable hydrogel (Dox@HFn Gel) through the formation of pH‐sensitive Schiff‐base bonds. After peritumoral injection, the Dox@HFn Gel is retained locally for up to three weeks, and released intact Dox@HFn gradually, which can not only facilitate tumor penetration through active transcytosis but also induce immunogenic cell death (ICD) to tumor cells to generate an antitumor immune response. Combining with anti‐programmed death‐1 antibody (αPD‐1), Dox@HFn Gel induces remarkable regression of orthotopic 4T1 breast tumors, further elicits a strong systemic anti‐tumor immune response to effectively suppress tumor recurrence and lung metastasis of 4T1 tumors after surgical resection. Besides, the combination of Dox@HFn GelL with anti‐CD47 antibody (αCD47) inhibits postsurgical tumor recurrence of aggressive orthotopic glioblastoma tumor model and significantly extends mice survival. This work sheds light on the construction of local hydrogels to potentiate antitumor immune response for improved cancer therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Ferritin Nanocaged Doxorubicin Potentiates Chemo‐Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death

Author

Chen, Yang, primary, Zeng, Linyuan, additional, Zhu, Hongzhang, additional, Wu, Qifei, additional, Liu, Rong, additional, Liang, Qian, additional, Chen, Bin, additional, Dai, Haitao, additional, Tang, Keyu, additional, Liao, Changli, additional, Huang, Yonghui, additional, Yan, Xiyun, additional, Fan, Kelong, additional, Du, Jin‐Zhi, additional, Lin, Run, additional, and Wang, Jun, additional

Published
2022
Full Text
View/download PDF

32. Ferritin Nanocaged Doxorubicin Potentiates Chemo‐Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death.

Author

Chen, Yang, Zeng, Linyuan, Zhu, Hongzhang, Wu, Qifei, Liu, Rong, Liang, Qian, Chen, Bin, Dai, Haitao, Tang, Keyu, Liao, Changli, Huang, Yonghui, Yan, Xiyun, Fan, Kelong, Du, Jin‐Zhi, Lin, Run, and Wang, Jun

Abstract

Although immunotherapy of hepatocellular carcinoma using immune checkpoint inhibitors has achieved certain success, only a subset of patients benefits from this therapeutic strategy. The combination of immunostimulatory chemotherapeutics represents a promising strategy to enhance the effectiveness of immunotherapy. However, it is hampered by the poor delivery of conventional chemotherapeutics. Here, it is shown that H‐ferritin nanocages loaded with doxorubicin (DOX@HFn) show potent chemo‐immunotherapy in hepatocellular carcinoma tumor models. DOX@HFn is constructed with uniform size, high stability, favorable drug loading, and intracellular acidity‐driven drug release. The receptor‐mediated targeting of DOX@HFn to liver cancer cells promote cellular uptake and tumor penetration in vitro and in vivo. DOX@HFn triggers immunogenic cell death to tumor cells and promotes the subsequent activation and maturation of dendritic cells. In vivo studies in H22 subcutaneous hepatoma demonstrate that DOX@HFn significantly inhibits the tumor growth with >30% tumors completely eliminated, while alleviating the systemic toxicity of free DOX. DOX@HFn also exhibits robust antitumor immune response and tumoricidal effect in a more aggressive Hepa1‐6 orthotopic liver tumor model, which is confirmed by the in situ magnetic resonance imaging and transcriptome sequencing. This study provides a facile and robust strategy to improve therapeutic efficacy of liver cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results